Free Trial
LON:4BB

4basebio Interim Earnings Results & Report

4basebio logo
GBX 517.50 -0.50 (-0.10%)
As of 11:41 AM Eastern

4basebio reported Interim earnings on September 28, 2026. The company reported EPS of -GBX 0.57.

Earnings Announcement Details

Quarter
Interim
Time
Before Market Opens

4basebio EPS Results

Actual EPS
-GBX 0.57
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

4basebio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

4basebio Interim Earnings FAQ

4basebio (LON:4BB) reported earnings of -GBX 0.57 per share for Interim. The report was announced on Monday, September 28, 2026.

4basebio Earnings Headlines

4basebio: Turning clinical credibility into commercial growth
I'm handing you this one free
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.tc pixel
4basebio Plc - Result of General Meeting
4basebio Plc - Result of General Meeting
See More 4basebio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 4basebio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 4basebio and other key companies, straight to your email.

About 4basebio

4basebio (LON:4BB) is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.

View 4basebio Profile